These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 32918114

  • 21. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
    Hua B, Lian X, Li K, Lee A, Poon MC, Zhao Y.
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677
    [Abstract] [Full Text] [Related]

  • 22. Hemophilia in Iran.
    Dorgalaleh A, Dadashizadeh G, Bamedi T.
    Hematology; 2016 Jun; 21(5):300-10. PubMed ID: 26914731
    [Abstract] [Full Text] [Related]

  • 23. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J, Berntorp E, Lindvall K, Björkman S.
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [Abstract] [Full Text] [Related]

  • 24. The long and short of it: using the new factor products.
    Dunn A.
    Hematology Am Soc Hematol Educ Program; 2015 Nov; 2015():26-32. PubMed ID: 26637697
    [Abstract] [Full Text] [Related]

  • 25. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
    Srichumpuang C, Rakmanotham A, Moonla C, Sosothikul D.
    Orphanet J Rare Dis; 2024 Mar 26; 19(1):135. PubMed ID: 38532451
    [Abstract] [Full Text] [Related]

  • 26. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
    Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML.
    Thromb Haemost; 2021 Aug 26; 121(8):1079-1086. PubMed ID: 33296943
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
    Zhao Y, Xiao J, Yang R, Wu R, Hu Y, Beckmann H, Wu J, Hou Q, Sun J.
    Pediatr Hematol Oncol; 2017 Apr 26; 34(3):138-148. PubMed ID: 28727494
    [Abstract] [Full Text] [Related]

  • 28. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M, Mannucci PM.
    Expert Opin Drug Saf; 2016 Oct 26; 15(10):1391-400. PubMed ID: 27367551
    [Abstract] [Full Text] [Related]

  • 29. Prophylaxis in real life scenarios.
    Fischer K, Konkle B, Broderick C, Kessler CM.
    Haemophilia; 2014 May 26; 20 Suppl 4():106-13. PubMed ID: 24762285
    [Abstract] [Full Text] [Related]

  • 30. Issues in pediatric haemophilia care.
    Giordano P, Franchini M, Lassandro G, Faienza MF, Valente R, Molinari AC.
    Ital J Pediatr; 2013 Apr 20; 39():24. PubMed ID: 23601343
    [Abstract] [Full Text] [Related]

  • 31. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay JW.
    J Manag Care Spec Pharm; 2016 Feb 20; 22(2):149-57. PubMed ID: 27015254
    [Abstract] [Full Text] [Related]

  • 32. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C, Marino R, Lambert C, Mangles S, Sommerer P, Rives V, Maro G, Malcangi G.
    Adv Ther; 2020 Jun 20; 37(6):2988-2998. PubMed ID: 32333327
    [Abstract] [Full Text] [Related]

  • 33. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF.
    J Thromb Haemost; 2014 Nov 20; 12(11):1788-800. PubMed ID: 25196897
    [Abstract] [Full Text] [Related]

  • 34. Prophylactic therapy for hemophilia in a developing country, Turkey.
    Kavakli K, Nişli G, Aydinok Y, Oztop S, Cetingül N, Aydoğdu S, Yalman O.
    Pediatr Hematol Oncol; 1997 Nov 20; 14(2):151-9. PubMed ID: 9089743
    [Abstract] [Full Text] [Related]

  • 35. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A, Moonla C, Sosothikul D.
    Haemophilia; 2023 Jan 20; 29(1):156-164. PubMed ID: 36409282
    [Abstract] [Full Text] [Related]

  • 36. The factor VIII treatment history of non-severe hemophilia A.
    Abdi A, Kloosterman FR, Eckhardt CL, Male C, Castaman G, Fischer K, Beckers EAM, Kruip MJHA, Peerlinck K, Mancuso ME, Santoro C, Hay CR, Platokouki H, van der Bom JG, Gouw SC, Fijnvandraat K, Hart DP, INSIGHT Study Group.
    J Thromb Haemost; 2020 Dec 20; 18(12):3203-3210. PubMed ID: 32877570
    [Abstract] [Full Text] [Related]

  • 37. Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A.
    Sun HL, McIntosh KA, Squire SJ, Yang M, Bartholomew C, Gue DS, Camp PG, Jackson SC.
    Haemophilia; 2017 Nov 20; 23(6):877-883. PubMed ID: 28851133
    [Abstract] [Full Text] [Related]

  • 38. Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B.
    Pauly N, Burrell A, Drelich D, Zhang X, Thiruvillakkat K, Nysenbaum J, Fiori A, Yan S.
    J Manag Care Spec Pharm; 2024 Oct 20; 30(10):1095-1105. PubMed ID: 38923896
    [Abstract] [Full Text] [Related]

  • 39. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.
    Steen Carlsson K, Höjgård S, Glomstein A, Lethagen S, Schulman S, Tengborn L, Lindgren A, Berntorp E, Lindgren B.
    Haemophilia; 2003 Sep 20; 9(5):555-66. PubMed ID: 14511294
    [Abstract] [Full Text] [Related]

  • 40. A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B.
    Rampotas A, Desborough MJR, Raza-Burton S, Taylor S, Wilkinson A, Hall GW, Shapiro S, Curry N.
    Haemophilia; 2020 Mar 20; 26(2):278-281. PubMed ID: 32083769
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.